Combination therapy with MDM2 and EFGR inhibitors
US9273031B2 · kind B2 · utility
12Cited by
8References
14Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Dec 16, 2014 |
| Grant date | Mar 1, 2016 |
| Priority date | — |
| Expiry date | Dec 16, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/44
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided is a method of treating a proliferative disease, condition, or disorder in a subject by administering a combination of an inhibitor of p53 and MDM2 binding and an EGFR inhibitor. Various embodiments of the disclosed methods provide a synergistic anti-proliferative or anti-apoptotic effect compared to administration of one agent alone.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.